Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers

Background: Chronic hepatitis B virus (HBV) infection is associated with hepatocellular carcinoma (HCC), and specific viral factors have been identified that may increase the risk for HCC development. However, the differences in these viral factors in chronic carriers who seldom develop HCC compared with HCC patients have not been adequately evaluated.

[1]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[2]  O. Yokosuka,et al.  Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. , 2006, Journal of hepatology.

[3]  J. Kao,et al.  Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[4]  Ding‐Shinn Chen,et al.  Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. , 2006, The Journal of infectious diseases.

[5]  C. Yurdaydın,et al.  From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). , 2006, Journal of hepatology.

[6]  Ding-Shinn Chen,et al.  Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. , 2006, The Journal of infectious diseases.

[7]  Ding‐Shinn Chen,et al.  High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. , 2006, Gastroenterology.

[8]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[9]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[10]  伊藤 清顕.  T1653 mutation in the box α increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection , 2006 .

[11]  M. Tong,et al.  Death From Liver Disease and Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection: A Prospective Study. , 2006, Gastroenterology & hepatology.

[12]  M. Yuen,et al.  T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Ding‐Shinn Chen,et al.  Therapeutic implications of hepatitis B virus genotypes , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[14]  G. François,et al.  Hepatitis B virus genotypes. , 2005, Vaccine.

[15]  Chien-Jen Chen,et al.  Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.

[16]  Y. Jeng,et al.  Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. , 2004, Gastroenterology.

[17]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[18]  V. Wong,et al.  Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma , 2004, Gut.

[19]  Ding‐Shinn Chen,et al.  Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. , 2004, Journal of hepatology.

[20]  A. Lok,et al.  Hepatitis B virus genotypes: Do they play a role in the outcome of HBV infection? , 2004, Hepatology.

[21]  F. Miselli,et al.  Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. , 2004, Gastroenterology.

[22]  K. Eguchi,et al.  High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection , 2004, Journal of gastroenterology and hepatology.

[23]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[24]  Ding‐Shinn Chen,et al.  Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. , 2003, Gastroenterology.

[25]  Makoto Arai,et al.  Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease , 2003, Hepatology.

[26]  H. Yotsuyanagi,et al.  Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. , 2002, Journal of hepatology.

[27]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[28]  T Ichida,et al.  Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan , 2001, Hepatology.

[29]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[30]  Makoto Nakanishi,et al.  Hepatitis B Virus Genotype Distribution among Chronic Hepatitis B Virus Carriers in Shanghai, China , 2001, Intervirology.

[31]  C. Hunt,et al.  Clinical relevance of hepatitis B viral mutations , 2000, Hepatology.

[32]  C. Chu.  Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma , 2000, Journal of gastroenterology and hepatology.

[33]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.

[34]  M. Baptista,et al.  High prevalence of 1762T 1764A mutations in the basic core promoter of hepatitis B virus isolated from black africans with hepatocellular carcinoma compared with asymptomatic carriers , 1999, Hepatology.

[35]  J. Nong,et al.  HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China , 1998, Journal of medical virology.

[36]  J. Lindsey,et al.  Choosing among generalized linear models applied to medical data. , 1998, Statistics in medicine.

[37]  S. Mishiro,et al.  Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates , 1998, Archives of Virology.

[38]  R. Purcell,et al.  Etiology, pathology, and treatment of hepatocellular carcinoma in North America , 1991 .

[39]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[40]  R. Sampliner,et al.  Spontaneous reactivation of hepatitis B in Chinese patients with Hbsag‐positive chronic active hepatitis , 1987, Hepatology.

[41]  E. ArévaloJiménez,et al.  Primary liver cancer , 1985 .

[42]  G. Vyas,et al.  Hepatitis B viral markers in patients with primary hepatocellular carcinoma in Taiwan. , 1981, Journal of the National Cancer Institute.

[43]  M. Kew,et al.  Hepatocellular cancer in Southern African blacks: HBeAg, anti-HBe, IgM-anti-HBc and other markers of hepatitis B. , 1981, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.